1. Home
  2. TBRG vs HURA Comparison

TBRG vs HURA Comparison

Compare TBRG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBRG
  • HURA
  • Stock Information
  • Founded
  • TBRG 1979
  • HURA 2009
  • Country
  • TBRG United States
  • HURA United States
  • Employees
  • TBRG N/A
  • HURA N/A
  • Industry
  • TBRG
  • HURA
  • Sector
  • TBRG
  • HURA
  • Exchange
  • TBRG NYSE
  • HURA Nasdaq
  • Market Cap
  • TBRG 271.5M
  • HURA 246.9M
  • IPO Year
  • TBRG N/A
  • HURA N/A
  • Fundamental
  • Price
  • TBRG $18.60
  • HURA $4.39
  • Analyst Decision
  • TBRG Buy
  • HURA
  • Analyst Count
  • TBRG 3
  • HURA 0
  • Target Price
  • TBRG $14.67
  • HURA N/A
  • AVG Volume (30 Days)
  • TBRG 66.0K
  • HURA 668.3K
  • Earning Date
  • TBRG 11-07-2024
  • HURA 02-15-2025
  • Dividend Yield
  • TBRG N/A
  • HURA N/A
  • EPS Growth
  • TBRG N/A
  • HURA N/A
  • EPS
  • TBRG N/A
  • HURA N/A
  • Revenue
  • TBRG $337,674,000.00
  • HURA N/A
  • Revenue This Year
  • TBRG $1.01
  • HURA N/A
  • Revenue Next Year
  • TBRG $6.05
  • HURA N/A
  • P/E Ratio
  • TBRG N/A
  • HURA N/A
  • Revenue Growth
  • TBRG 0.26
  • HURA N/A
  • 52 Week Low
  • TBRG $7.55
  • HURA $2.84
  • 52 Week High
  • TBRG $18.83
  • HURA $14.60
  • Technical
  • Relative Strength Index (RSI)
  • TBRG 63.03
  • HURA N/A
  • Support Level
  • TBRG $17.71
  • HURA N/A
  • Resistance Level
  • TBRG $18.47
  • HURA N/A
  • Average True Range (ATR)
  • TBRG 0.60
  • HURA 0.00
  • MACD
  • TBRG -0.19
  • HURA 0.00
  • Stochastic Oscillator
  • TBRG 35.32
  • HURA 0.00

About TBRG TRUBRIDGE INC

TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: